ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

• members of families in whom at least one member has a known disease-associatedutation in one of the major genes that cause f-FTLD: MAPT, GRN, C9orf72 (or othergenes)
• an autosomal dominant family history of a FTLD syndrome (without a known gene)verified by medical record review or well-documented family history including familybers with a medical history consistent with FTLD or a related disorder.

        Sporadic participants should be symptomatic with no known family history nor a geneticutation indicating f-FTLD. All sporadic participants must have an FTLD syndrome as ag diagnosis; those determined by ALLFTD clinicians to have non-FTLD diagnoses willbe excluded from longitudinal visits, but their baseline visit will be included inve datasets. For inclusion in the longitudinal follow-up, participants should meeth criteria for one of the following FTLD syndromes:Progressive Supranuclear Palsy (PSP)variant Primary Progressive Aphasia (svPPA)uent variant Primary Progressive Aphasia (nfvPPA)Corticobasal Degeneration (CBD)/Corticobasal Syndrome (CBS)Behavioral variant Frontotemporal dementia (bvFTD)Frontotemporal Dementia with Amyotrophic Lateral Sclerosis (FTD/ALS)Biofluid-Focused Arm Inclusion CriteriaParticipants enrolled in the biofluid arm may be either f-FTLD or s-FTLD. All generalusion criteria apply. Participants should meet research criteria (as specified above)y FTLD syndrome or meet familial FTLD inclusion criteria. Because the biofluid armdo not undergo the same detailed clinical and functional assessments requiredhe longitudinal arm, participants may be included regardless of primary language, asg as an appropriately translated consent is available.usion Criteria:Known presence of a structural brain lesion (e.g. tumor, cortical infarct) that couldbly explain symptoms in a symptomatic participant.Known presence of an Alzheimer's disease causing mutation in PSEN1, PSEN2 or APP; orbiomarker evidence for Alzheimer's disease as a cause of the clinical syndrome.A previous history of Korsakoff encephalopathy, severe alcohol dependence (within 5years of onset of dementia), frequent alcohol or other substance intoxication, orher neurological disorder.vidence through history or laboratory testing of uncorrected B12 deficiency (B12 <95% of local laboratory's normal value), unregulated hypothyroidism (TSH >150% of), HIV positive, renal failure (creatinine > 2), liver failure (ALT or AST > two), respiratory failure that requires supplemental oxygen, large confluentwhite matter lesions, significant systemic medical illnesses such as deterioratingdiovascular disease.Current medication likely to affect CNS functions in the opinion of the site PI.he site investigator's opinion, the participant cannot complete sufficient keyudy procedures. The participant may be enrolled into the biofluid-focused arm ifhey can tolerate a blood draw and short clinical exam, but must be able to complete75% of study procedures for enrollment into the longitudinal arm.